)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Hyloris Pharmaceuticals (HYL) investor relations material
Hyloris Pharmaceuticals H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary25 Sep, 2025
Executive summary
Recurring royalties increased nearly 30% year-over-year to €2.9 million, reflecting strong commercial traction for three products.
Portfolio expanded to 26 products and candidates, with four new additions in H1 2025 and a target of 30 by year-end.
Achieved FDA approval for Tranexamic Acid RTU, completed pivotal trial for Dofetilide IV, and reported positive results for Atomoxetine liquid.
Signed new international licensing agreements and advanced late-stage collaborations for Valacyclovir oral suspension and XTRAZA.
Maintained financial discipline with a contained net loss of €3.5 million, equity of €28.9 million, and cash of €18.6 million.
Financial highlights
Revenues for H1 2025 were €3.0 million, down from €4.2 million in H1 2024 due to the absence of milestone payments; royalties rose 30% year-over-year.
Operating loss (EBIT) was €3.5 million, compared to €4.0 million in H1 2024.
R&D expenses decreased 6% year-over-year, while G&A expenses dropped 30%.
Cash and cash equivalents stood at €18.6 million as of June 30, 2025, down from €23.6 million at year-end 2024.
Basic and diluted loss per share was €(0.13), compared to €(0.12) in H1 2024.
Outlook and guidance
On track to expand the portfolio to 30 products and candidates by year-end 2025.
Cash position and equity base provide funding for ongoing R&D and growth plans.
Preference to out-license cardiovascular assets for U.S. distribution; access to financial and strategic partners if additional funding is needed.
Additional strategic partnerships and out-licensing milestones anticipated in coming months.
U.S. cardiovascular commercialization strategy under continued development.
Maxigesic IV: U.S. J-code impact on sales?
Suramin IV: PRV sale proceeds expectation?
Valacyclovir oral suspension: Commercial launch plan?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Hyloris Pharmaceuticals earnings date
H2 202526 Mar, 2026
Next Hyloris Pharmaceuticals earnings date
H2 202526 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Hyloris Pharmaceuticals SA is a Belgian specialty pharmaceutical company that develops reformulated and repurposed medicines. Its portfolio focuses on improving existing drugs to address unmet clinical needs across hospital and emergency care settings. The company engages in regulatory development and commercialization through partnerships. It is headquartered in Liège, Belgium, and its shares are listed on the EURONEXT Brussels.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage